Danaher Corp
DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3027% above fair value
$227.97−4.26 (-1.83%)
Close on Nov 2, 2026Market cap $160.26BP/E 40.5Yield –
Danaher Biotechnology — Adjusted EBITDA by Quarter
Biotechnology — Adjusted EBITDA ($M)
Danaher Biotechnology — Adjusted EBITDA: $800M in Q3 2026, up 13.2% from a year earlier.
Latest, Q3 2026
800
Period ended Sep 30, 2026
Change on a year earlier
+13.2%
707 in Q3 2025
History
19 quarters
Since Q1 2022
Sources
11
Documents cited below
Where the Q3 2026 figure comes from
Source: Danaher IR — nongaap_2026Q3 ↗
Reported in Danaher Non-GAAP Reconciliations & Supplemental Data (8-K / IR PDF).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Biotechnology — Adjusted EBITDA ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 800 | +13.2% | Danaher IR — nongaap_2026Q3 ↗ |
| Q2 2026 | Jun 30, 2026 | 827 | +3.8% | Danaher IR — nongaap_2026Q2 ↗ |
| Q1 2026 | Mar 31, 2026 | 808 | +14.9% | Danaher IR — nongaap_2026Q1 ↗ |
| Q4 2025 | Dec 31, 2025 | 809 | +6.6% | Danaher IR — nongaap_2025Q4 ↗ |
| Q3 2025 | Sep 30, 2025 | 707 | +9.8% | Danaher IR — nongaap_2026Q3 ↗ |
| Q2 2025 | Jun 30, 2025 | 797 | +12.1% | Danaher IR — nongaap_2026Q2 ↗ |
| Q1 2025 | Mar 31, 2025 | 703 | +20.2% | Danaher IR — nongaap_2026Q1 ↗ |
| Q4 2024 | Dec 31, 2024 | 759 | +10.6% | Danaher IR — nongaap_2025Q4 ↗ |
| Q3 2024 | Sep 30, 2024 | 644 | -4.0% | Danaher IR — nongaap_2025Q3 ↗ |
| Q2 2024 | Jun 30, 2024 | 711 | -8.7% | Danaher IR — nongaap_2025Q2 ↗ |
| Q1 2024 | Mar 31, 2024 | 585 | -31.4% | Danaher IR — nongaap_2025Q1 ↗ |
| Q4 2023 | Dec 31, 2023 | 686 | -27.9% | Danaher IR — nongaap_2024Q4 ↗ |
| Q3 2023 | Sep 30, 2023 | 671 | -27.7% | Danaher IR — nongaap_2024Q3 ↗ |
| Q2 2023 | Jun 30, 2023 | 779 | -27.3% | Danaher IR — nongaap_2024Q2 ↗ |
| Q1 2023 | Mar 31, 2023 | 853 | -20.4% | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2022 | Dec 31, 2022 | 952 | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q3 2022 | Sep 30, 2022 | 928 | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2022 | Jun 30, 2022 | 1,072 | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2022 | Mar 31, 2022 | 1,072 | – | Danaher IR — nongaap_ex_veralto ↗ |
Cite this data
StockData. (2026). Danaher Biotechnology — Adjusted EBITDA ($M), quarterly Q1 2022–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/adj-ebitda-biotech
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.